Health Catalyst (NASDAQ:HCAT) – Investment analysts at William Blair boosted their FY2019 EPS estimates for shares of Health Catalyst in a research note issued on Wednesday, November 13th. William Blair analyst R. Daniels now forecasts that the company will earn ($1.19) per share for the year, up from their prior forecast of ($1.20). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Health Catalyst’s Q4 2019 earnings at ($0.33) EPS, Q1 2020 earnings at ($0.29) EPS, Q2 2020 earnings at ($0.24) EPS, Q3 2020 earnings at ($0.34) EPS and FY2020 earnings at ($1.02) EPS.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald started coverage on Health Catalyst in a research note on Tuesday, October 29th. They set an “overweight” rating and a $47.00 price target on the stock. Svb Leerink assumed coverage on Health Catalyst in a report on Monday, August 19th. They issued an “outperform” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Health Catalyst in a report on Monday, August 19th. They issued an “overweight” rating and a $50.00 price objective for the company. SunTrust Banks assumed coverage on Health Catalyst in a report on Monday, August 19th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Leerink Swann assumed coverage on Health Catalyst in a report on Monday, August 19th. They issued an “outperform” rating and a $55.00 price objective for the company. Ten research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $49.33.

Health Catalyst stock opened at $34.38 on Monday. The company’s 50-day moving average price is $30.60. Health Catalyst has a fifty-two week low of $26.00 and a fifty-two week high of $49.85.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $39.40 million for the quarter, compared to analysts’ expectations of $37.77 million. The company’s revenue was up 19.8% on a year-over-year basis.

Several hedge funds have recently modified their holdings of HCAT. Nepsis Inc. acquired a new position in shares of Health Catalyst in the 3rd quarter valued at about $3,101,000. Conestoga Capital Advisors LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at about $3,249,000. Emerald Advisers LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at about $631,000. Emerald Mutual Fund Advisers Trust acquired a new position in Health Catalyst in the 3rd quarter worth about $542,000. Finally, Dean Capital Investments Management LLC acquired a new position in Health Catalyst in the 3rd quarter worth about $485,000. 7.28% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Recommended Story: Why is the LIBOR significant?

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.